Inovio's Revolutionary DNA Immunotherapy Product Slated for Trials in 2014, by BrokerBank Securities, Inc.

NEW YORK, Feb. 26, 2014 /PRNewswire/ -- Inovio Pharmaceuticals (NYSEMKT: INO) plans to put its HPV-related cancer and pre-cancer treatment, VGX-3100, through Phase II trials in 2014.

Inovio Pharmaceuticals (INO) recently announced that its revolutionary treatment, VGX-3100, is slated for a 2014 phase II trial for its efficacy treating cervical dysplasia. The treatment is just one of numerous products that Inovio has in the pipeline.

In addition to VGX-3100, Inovio is prepping treatments and vaccines for cervical, head and neck, prostate, breast, and lung cancers. Further down the pipeline, the company is developing revolutionary vaccines for HIV, hepatitis B, malaria, and hepatitis C. Given the breadth and pervasiveness of the diseases the company is targeting, Inovio estimates that its drugs could eventually be used to treat billions of people.

Inovio's products are unique in the field of DNA vaccines, which engineer the body's DNA platforms to achieve desired results. Specifically, Inovio's active immunotherapy treatments target t-cells for use against the body's diseased cells. Inovio then uses a unique technological product called an electroporation device to open pores in the targeted cells membrane. The treatment enters the cells through those pores, creating a powerful immune system resistant to the targeted disease.

The company has an experienced research leadership team, strong ties to respected medical institutions, and a $400 million developmental partnership with Roche, a worldwide leader in the development of drugs and treatments for cancer. As Inovio's treatments come to market, the company has a tremendous opportunity to save patients for devastating diseases while also capitalizing on a massive market.

For more information on Inovio Pharmaceuticals including a list of the products in the pipeline, check out our free company report here: http://bit.ly/INO-AnalystReport  copy and paste may be required

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Marc Bonacci, Chief Analyst. An outsourced research services provider represented by Marc Bonacci, Chief Analyst, has written and reviewed the information in this article or report. BrokerBank Securities, Inc. or Small Cap Street, LLC is not entitled to veto, interfere or alter the articles, documents or report once created and reviewed by the outsourced research provider represented by Marc Bonacci, Chief Analyst. Small Cap Street, LLC is the party responsible for hosting the full analyst report on smallcapstreet.com. Marc Bonaccci, Chief Analyst, is the author of research report. BrokerBank Securities, Inc. is the party responsible for issuing this press release. Small Cap Street has compensated Marc Bonacci one hundred dollars for the right to disseminate this press release and report. Information in this release is fact checked and produced on a best efforts basis by Marc Bonacci, Chief Analyst.

NOT FINANCIAL ADVICE

BrokerBank Securities, Inc. or Small Cap Street, LLC makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Companies mentioned have not compensated BrokerBank Securities, Inc. Small Cap Street, LLC or Marc Bonacci, Chief Analyst, for the creation or dissemination of this press release. BrokerBank Securities, Inc. or Small Cap Street, LLC. is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by BrokerBank Securities, Inc. or Small Cap Street, LLC. whatsoever for any direct, indirect or consequential loss arising from the use of this document. BrokerBank Securities, Inc. or Small Cap Street, LLC. expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. BrokerBank Securities, Inc. or Small Cap Street, LLC. does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.

SOURCE BrokerBank Securities, Inc.